DLBCL 免疫治疗中的巨噬细胞吞噬检查点：从 CD47 到 CD200 的证据成熟度框架

Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.

弥漫性大B细胞淋巴瘤（DLBCL）的治疗正采用范围不断扩大的抗体类和细胞类疗法，但巨噬细胞吞噬检查点仍常被逐个分子地讨论。

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

靶向 CD19、CD20 和 CD22 的床旁制备三特异性 CAR-T 细胞首次人体试验的安全性与临床结局

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

大辩论：CAR-T 细胞疗法对比双特异性抗体治疗 B 细胞淋巴瘤

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

开发串联犬 CAR-T 细胞以支持侵袭性 B 细胞淋巴瘤的比较研究

Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma.

CD19 CAR-T 细胞治疗滤泡性淋巴瘤后重度银屑病长期缓解

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.

短程递增给药 glofitamab 使弥漫大 B 细胞淋巴瘤患者抗 CD19 CAR-T 细胞治疗失败后死亡风险减半：LYSA BiCAR 预设外部对照臂 II 期试验最终结果

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final result

基于已发表 Kaplan-Meier 曲线重建的个体患者数据对复发/难治性滤泡性淋巴瘤当代二线及后线治疗进行持久性基准评估

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual

弥漫大 B 细胞淋巴瘤的免疫治疗：从单克隆抗体到细胞治疗（叙述性综述）

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。